comprehensive -WSS

comprehensive

author：leisure time 2025-09-28 23:49:30 - browse：92

Axovant Sciences(AXON) is the main event in biotech’s September cavalcade of clinical trial readouts, but while we wait, it’s a good idea to prep for important — and stock-moving — data releases from Zogenix(ZGNX) and Amicus Therapeutics(FOLD).

Zogenix’s lead drug, called ZX008, is a low-dose liquid formulation of the old serotonin booster fenfluramine. The company is developing ZX008 to treat children with Dravet syndrome, a rare and severe type of epilepsy.

You might remember fenfluramine as part of the “fen-phen” obesity regimen that was pulled from the market in 1997 because fenfluramine (at a higher dose) caused severe damage to people’s heart valves.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Oral obesity drug from Viking Therapeutics hits key early target

knowledge

WSS

Bird flu reported in person exposed to presumably infected cattle

Trial using CRISPR to edit HIV out of cells disappoints

UnitedHealth, in a surprise, takes aim at Steward’s physician group

Scientific mystery highlights the blind spots in genomics databases

Alzheimer's risk factor APOE4 may be a distinct form of the disease

Four alarming medical procedures we’re glad history forgot

entertainment

comprehensive

focus

Supreme Court strikes down use of affirmative action

Iran's president begins a rare visit to Africa 'to promote economic diplomacy'

23andMe had bad news about my health. I wish a person had delivered it

Mass General Brigham physicians react to latest merger step

How to save PrEP access — and even expand it

Grail's uphill battle for Medicare to cover its cancer screening test

23andMe had bad news about my health. I wish a person had delivered it

Alzheimer's risk factor APOE4 may be a distinct form of the disease

Jerome Adams on the need for new antivirals for Covid

Tommy Tuberville reverses his claim that white nationalists are unfairly labeled racist

leisure time

Oral obesity drug from Viking Therapeutics hits key early target

Pancreatic cancer is often deadly, but new discoveries are raising hope

Inflation cooled significantly in June, bringing price hikes close to normal levels

Companies helping big Covid

First Opinion on colorectal cancer screening: letter and response

EU fines Illumina $475 million over Grail acquisition

focus

knowledge

entertainment

entertainment